Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2010
11/30/2010US7842822 (3aS, 4S, 9bS)-4-(4-Hydroxy-phenyl)-1,3a,4,9b-tetrahydro-3H-2,5-dioxa-cyclopenta[a]naphthalen-8-ol, used for the treatment of benign prostatic hyperplasia, cardiovascular diseases, neurodegenerative disorders, incontinence, nervous system disorders, gastrointestinal disorders and osteoporosis
11/30/2010US7842820 Sulfonylpyrroles
11/30/2010US7842819 Derivatives for modulation of ion channels
11/30/2010US7842817 Such as 1,3-Bis(4-chlorobenzyl)-1,3-dihydrobenzoimidazol-2-ylideneamine; cardiovascular, cognitive, gastrointestinal, respiratory, psychological, urogenital, nervous system, sleep and metabolic disorders
11/30/2010US7842816 Mitogen-activated protein kinase kinase inhibitors such as 2-amino-3-methylbutyric acid 2-{[6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3H -benzoimidazole-5-carbonyl]-aminooxy}-ethylester, used for the treatment of diseases, such as cancer and inflammation in mammals
11/30/2010US7842812 Substituted 5-aminomethy1-1H-pyrrole-2-carboxylic acid amides
11/30/2010US7842808 Anti-migraine spirocycles
11/30/2010US7842807 Process for preparing the calcium salt of rosuvastatin
11/30/2010US7842805 1-arylamino-phthalazines such as 5-Fluorophthalazin-1-yl)-(4-methoxyphenyl)-methyl-amine or 4-arylamino-benzo[d][1,2,3]triazines such as Benzo[d][1,2,3]triazin-4-y1-(4-methoxy-pheny1)-methyl-amine, used as anticarcinogenic agents or for the treatment of psoriasis, autoimmune diseases and fungi infections
11/30/2010US7842803 Nicotinic acetylcholine receptor ligands 101
11/30/2010US7842802 Vinorelbine derivatives
11/30/2010US7842791 Dispersible pharmaceutical compositions
11/30/2010US7842730 includes rapidly excretable perfluororganic compounds e.g. perfluordecalin, perfluoractilbromide, a perfluoroganic additive embodied in the form of a mixture of perfluorinated tertiary amines contains perfluorotripropylamine and coproducts; and phospholipids in the form of a water-salt dispersion
11/30/2010US7842729 substituted ethylene diamines such as N-Geranyl-N'-(2-adamanthyl)ethane-1,2-diamine, used for the treatment of leprosy or tuberculosis caused by mycobacterial infections
11/30/2010US7842728 Neuronal sodium channel antagonist with pyrethroids, recombinant nucleopolyhedroviruses expressing insect toxin, organophosphates, carbamates, formamidines, macrocyclic lactones, amidinohydrazones, GABA antagonists and/or acetylcholine receptor ligands; crop protection
11/30/2010US7842727 Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid
11/30/2010US7842726 Carnitine derivative, salt thereof, external skin preparation and cosmetic material
11/30/2010US7842725 dimethicone surfactants are PEG-8 to PEG-12 linear dimethicone surfactants; C2-C4 alcohol and water; hand and skin care product; microbiocides
11/30/2010US7842724 Pharmaceutical gallium compositions and methods
11/30/2010US7842722 contain cobeadlets comprising vitamin E and carotenoids in the form of Vitamin A, lutein and/or zeaxanthing; further contain Vitamin C, copper and zinc; improving ocular nutrition
11/30/2010US7842720 Anticancer and antiprotozoal dihydroartemisinene and dihydroartemisitene dimers with desirable chemical functionalities
11/30/2010US7842719 Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus
11/30/2010US7842718 thiophene sulfonamide derivatives such as 5-Chloro-N-[(S)-2-hydroxy-1-phenylethyl]thiophene-2-sulfonamide, that inhibit the production of beta amyloid protein from amyloid precursor protein; capable of passing through the blood-brain barrier, used for treatment of Alzheimer's disease and Down's syndrome
11/30/2010US7842717 Forming duloxetine, or salt thereof; serotonine receptor antagonist
11/30/2010US7842716 Treating vascular events with statins by inhibiting PAR-1 and PAR-4
11/30/2010US7842715 (3'S)-1'-(4-phenoxybenzoyl)-1,3'-bipyrrolidine, used for treating nervous system disorders, such as Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, obesity and sleep disorders
11/30/2010US7842714 A topical aqeous opthalmic solution containing ketorolac tromethamine, carboxymethyl cellulose, medium viscosity, carboxymethyl cellulose, high viscosity, NaCl, sodium citrate dihydrate, a buffer selected from NaOH and HCl to adjust pH to about 6, and water;
11/30/2010US7842713 Fused phenyl amido heterocyclic compounds
11/30/2010US7842712 Indazolinone compositions useful as kinase inhibitors
11/30/2010US7842711 administering 1H-indazole-3-carboxamide's such as N-(pyridin-4-yl)-5-isoquinolin-4-yl-1H-indazole-3-carboxamide, in an effective amount to inhibiting Plasmodium falciparum parasite
11/30/2010US7842710 5-fluoro-N-{2-[1-(isopropylamino)ethyl]phenyl}-1,3-dimethyl-1H-pyrazole-4-carboxamide; with extenders and/or surface-active materials; microbiocide, fungicide, bactericide; low application rates
11/30/2010US7842709 Method for treating inflammatory diseases of the digestive tract
11/30/2010US7842707 Peptidase inhibitors
11/30/2010US7842706 Pharmaceutical composition
11/30/2010US7842705 Curcumin analogs with anti-tumor and anti-angiogenic properties
11/30/2010US7842704 Biphenyl-2-ylcarbamic Acid 1-{9-[2-(4-Hydroxy-2-oxo-2,3-dihydrobenzothiazol-7-yl)-ethylamino]nonyl}piperidin-4-yl Ester Bis(trifluoroacetate) Salt; chronic obstructive pulmonary disease, asthma; bronchodilators
11/30/2010US7842703 Pain therapy; headaches; neurodegenerative diseases; stroke; skin disorders; antiischemic agents; Huntington's disease; antiulcer agents; inflammatory bowel disorders;amyotropic lateral sclerosis
11/30/2010US7842702 Treatment for irritable bowel syndrome
11/30/2010US7842701 tyrosine kinase inhibitors such as 3-amino-2-(2-chloro-5-hydroxyphenyl)-7-(3-morpholin-4-ylpropoxy)-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one, used as anticarcinogenic or antiproliferative agents
11/30/2010US7842700 isopropyl ester of N-(2,6-dichlorobenzoyl)-4-(6-iodo-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-3(2H)-yl)-L-phenylalanine; 4 integrin inhibitor; antiinflammatory agent; rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis, asthma; preservation stability, humidity resistance or solubility;
11/30/2010US7842699 administering 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile or salts, for the treatment of dermatitis, Crohn's disease, inflammatory bowel disease, transplant rejection, lupus, multiple sclerosis, arthritis, psoriasis, diabetes and autoimmune diseases
11/30/2010US7842698 Autoimmune diseases; antiinflamamtory agents, cardiovascular disorders; neurodegenerative diseases, kidney diseases, anticancer agents; platelet aggregation
11/30/2010US7842697 such as 2-(4-{4-[N'-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidino]-butyl}phenoxy)-N-(3-dimethylaminopropyl)acetamide dimethanesulfonate, having prolonged pharmacodynamic half-life on mucosal surfaces, used for the treatment of cardiovascular disorders
11/30/2010US7842696 such as 4-Benzenesulfinyl-N-{2-oxo-2-[4-(2-trifluoromethyl-benzoyl)-piperazin-1-yl]-ethyl}-benzamide, used for the treatment of syndrome X, obesity, insulin resistance, dyslipidemia and cardiovascular diseases
11/30/2010US7842695 such as 1-{1-[5-(4-Fluorophenyl)pyridin-2-yl]-5-furan-2-yl-1H-pyrazol-4-ylmethyl}-4-methylpiperazine, exhibiting selective serotonin receptor antagonistic properties, used for the prophylaxis and/or treatment of psychoses, neurological disorders, amyotrophic lateral sclerosis, eating and vision disorders
11/30/2010US7842694 glucokinase activator 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}-N-(5-methylpyrazin-2-yl)benzamide or a salt ; deprotecting silanol group with an acid; type 2 diabetes
11/30/2010US7842693 For therapy of rheumatoid arthritis, multiple sclerosis, transplant rejection, dermnatitis, eczema, urticaria, vasculitis, inflammatory bowel disease, food allergy and encephalomyelitis
11/30/2010US7842692 Azaindole derivative having PGD2 receptor antagonistic activity
11/30/2010US7842691 Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide
11/30/2010US7842690 Cyclic hydroxylamine as psychoactive compounds
11/30/2010US7842689 Cyclic hydroxylamine as psychoactive compounds
11/30/2010US7842688 Organic compounds
11/30/2010US7842687 Cephalotaxane derivatives and their processes of preparation and purification
11/30/2010US7842686 Calcitonin gene-related peptide (CGRP) receptor antagonists, such as 2-(2-Butyl-3-oxo-2H-benzo[b][1,4]thiazin-4(3H)-yl)-N-(2,5-dioxo-1',3'-dihydrospiro[imidazolidine-4,2'-indene]-5'-yl)acetamide, used as analgesics
11/30/2010US7842685 Sphingosine-1-phosphate (S1P) receptor modulating agents such as 1-((3-fluoro-4-(5(1-phenylcyclopropyl)thiazolo[5,4-b]pyridin-2-yl)phenyl)methyl)azetidine-3-carboxylic acid, used for the treatment of autoimmune diseases; side effect reduction
11/30/2010US7842684 Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity
11/30/2010US7842683 Beta-lactam antibiotics and beta-lactamase inhibitors provide significant neurotropic effects in warm-blooded vertebrates evidenced inter alia by anxiolytic and antiaggressive behavior modification and enhanced cognition
11/30/2010US7842682 Boronated metal-phthalocyanines, process for their preparation, pharmaceutical compositions comprising them and use thereof
11/30/2010US7842681 Reducing platelets in mammals blood and preventing/treating pro-thrombotic conditions and diseases via inhibitors of anti-apoptotic Bcl-2 family protein members
11/30/2010US7842680 Diene and triene compounds and formulations
11/30/2010US7842678 Compositions comprising oligosaccharides
11/30/2010US7842677 use in the field of neuroprotection and cancer treatment (neuroblastoma tumors)
11/30/2010US7842676 Fixed ratio drug combination treatments for solid tumors
11/30/2010US7842675 Deuterium-enriched capecitabine
11/30/2010US7842674 administering to a surgery patient in whom p53 protein is elevated as a result of a stress, a modified double stranded siRNA to down-regulate p53 in the patient
11/30/2010US7842673 introducing an oligonucleotide into a donor cell, particularly a stem cell, and contacting the target cell with the donor cell under conditions permitting the donor cell to form a gap junction channel composed of connexin 43 with the target cell, thus donor cell delivers oligonucleotide to target cell
11/30/2010US7842672 Phosphonate inhibitors of HCV
11/30/2010US7842497 Production of isoprenoids
11/30/2010US7842470 Method for pharmacoperones correction of GnRHR mutant protein misfolding
11/30/2010US7842377 comprises alginates; anticancer agents; therapeutic vascular occlusions (embolizations)
11/30/2010US7842311 for oral dosage; for treatment of pain; sustained release
11/30/2010US7842310 Pharmaceutical compositions in particulate form
11/30/2010US7842309 Tamper-resistant oral opioid agonist formulations
11/30/2010US7842290 involved in the adaptation of microorganisms to its environment, particularly the identification of genes responsible for the virulence of a pathogenic microorganisms
11/30/2010CA2624621C Pyrazine derivatives
11/30/2010CA2620398C Method of combating infection
11/30/2010CA2607499C Histamine-3 receptor antagonists
11/30/2010CA2583492C Naphthalene and isoquinoline derivatives bearing a pyridyl group for the treatment of skin lesions
11/30/2010CA2577288C Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
11/30/2010CA2559640C Means for transdermal administration of nicotine
11/30/2010CA2538205C Nucleosides with anti-hepatitis b virus activity
11/30/2010CA2519938C Prostaglandin analogs as ep4 receptor agonists
11/30/2010CA2515151C Non-nucleoside reverse transcriptase inhibitors
11/30/2010CA2513440C Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
11/30/2010CA2497868C Heterocyclic compounds
11/30/2010CA2497444C Pyrazolopyrimidines as cyclin dependent kinase inhibitors
11/30/2010CA2495118C Method for the separation of intermediates which may be used for the preparation of escitalopram
11/30/2010CA2482858C Tricyclic thrombin receptor antagonists
11/30/2010CA2477208C Substituted phenylalkanoic acid derivatives and use thereof
11/30/2010CA2473038C Weight management system for obese animals
11/30/2010CA2460682C Ester compound and medical use thereof
11/30/2010CA2456817C Alkyne-aryl-naphthyridin-4 (1h)-one derivatives as type iv phosphodiesterase inhibitor
11/30/2010CA2450076C Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or a diagnostic agent and pharmaceutical preparations containing said compounds
11/30/2010CA2449352C Nsaid formulation comprising a granular composition and an extra-granular composition
11/30/2010CA2440218C Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use as adenosine receptor-selective ligands
11/30/2010CA2432809C Heteroaryl urea neuropeptide y y5 receptor antagonists
11/30/2010CA2419741C Anti-constipation and cathartic composition comprising bi-cyclic 15-keto prostaglandin derivatives
11/30/2010CA2412804C Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives
11/30/2010CA2396129C Method and formulation for treating resistance to antihypertensives and related conditions
11/30/2010CA2362932C Pharmaceutical composition containing proton pump inhibitors
1 ... 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 ... 7860